Company news

Share this article:
According to an internal memo, Pfizer is planning to end manufacturing of heart disease medications, Forbes reported, while also scaling back development of anemia, osteoporosis, liver, muscle, obesity and peripheral artery disease treatments. The company will instead focus on five therapeutic areas: Alzheimer's; diabetes, immune disorders and inflammation; cancer; pain and mental illness.

In an effort to control costs, GlaxoSmithKline may cut as many as 850 R&D jobs in the US and UK, according to a Wall Street Journal report.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions